XBiotech Inc.

Equities

XBIT

CA98400H1029

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 03:00:50 2024-06-20 pm EDT			5-day change	1st Jan Change
5.325 ^USD	+1.24%		-15.35%	+33.75%

Jun. 18	XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer	CI
May. 10	XBiotech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

XBiotech Inc. Appoints Alice Gottlieb to Its Scientific Advisory Board

September 20, 2018 at 08:00 am EDT

XBiotech Inc. announced the addition of Alice Gottlieb, M.D., Ph.D., to its scientific advisory board. Dr. Gottlieb is currently Professor of Dermatology at New York Medical College and former Chair of Dermatology and Dermatologist-in-Chief at the Tufts Medical Center and Tufts University School of Medicine.

Latest news about XBiotech Inc.

XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer	Jun. 18	CI
XBiotech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 10	CI
XBiotech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 15	CI
XBiotech Inc. to Begin Constructing New R&D Facility on Its 48-Acre Campus	Jan. 04	CI
XBiotech Inc. announced that it expects to receive $10 million in funding	Jan. 02	CI
Xbiotech Appoints Alan Kivitz M.D. Lead Investigator & Study Chairman for Its Clinical Research Program for Natrunix in Rheumatoid Arthritis	Nov. 14	CI
XBiotech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Xbiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, A Novel Candidate Therapy for Stroke	23-09-26	CI
XBiotech Inc.(NasdaqGS:XBIT) dropped from S&P Global BMI Index	23-09-18	CI
Xbiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer	23-08-30	CI
XBiotech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
Tranche Update on XBiotech Inc.'s Equity Buyback Plan announced on May 17, 2023.	23-06-20	CI
XBiotech Inc.'s Equity Buyback announced on May 17, 2023, has expired with 3,561 shares, representing 0.01% for $0.01 million.	23-06-14	CI
XBiotech Gets FDA Approval for Phase 2 Study of Potential Treatment for Rheumatoid Arthritis	23-05-22	MT
XBiotech Inc. announces an Equity Buyback for $80 million worth of its shares.	23-05-17	CI
XBiotech Inc. authorizes a Buyback Plan.	23-05-16	CI
XBiotech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
XBiotech Enrolls First Subject in Phase 1 Trial of Stroke Therapy Hutrukin; Shares Rise	23-04-17	MT
XBiotech Inc. Announces Executive Changes	23-02-15	CI
XBiotech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-09	CI
XBiotech Study of Natrunix Therapy to Treat Colorectal Cancer Enrolls First Patient	22-10-13	MT
XBiotech Inc. Announces First Patient Enrolled into the French National Cancer Institute Sponsored Phase I/Ii/Iii Clinical Study for Natrunix™ Therapy for Colorectal Cancer	22-10-13	CI
XBiotech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-10	CI
XBiotech Inc.(NasdaqGS:XBIT) dropped from Russell 2500 Index	22-06-24	CI
XBiotech Inc.(NasdaqGS:XBIT) dropped from Russell Small Cap Comp Value Index	22-06-24	CI

Chart XBiotech Inc.

Duration

Period

More charts

Company Profile

XBiotech Inc. is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies for treating a variety of diseases, such as inflammatory conditions like rheumatology, infectious disease, cardiovascular disease and cancer. The Company's True Human monoclonal antibodies are derived from human donors that mount a natural human immune response. The Company is focused on therapies that block a potent substance, known as interleukin-1 alpha (IL-1a), that mediates a number of pathophysiological processes including tissue breakdown (i.e. synovium, cartilage, bone), paraneoplastic angiogenesis and tumor stroma remodeling, formation of blood clots, malaise, muscle wasting and general inflammation. It has various candidate products including Natrunix. It has a clinical-stage therapeutic for methicillin resistant Staphylococcus aureus (MRSA), and several pre-clinical-stage therapeutics, including an oral delivery antibody therapeutic for colon infection by C. difficile.

Sector

Biotechnology & Medical Research

Calendar

2024-06-19 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
XBIOTECH INC.	+33.75%	160M
VERTEX PHARMACEUTICALS INCORPORATED	+15.80%	121B
REGENERON PHARMACEUTICALS, INC.	+18.63%	112B
ARGENX SE	+4.43%	22.57B
BIONTECH SE	-18.13%	20.82B
BEIGENE, LTD.	-13.60%	16.3B
GENMAB A/S	-16.61%	16.19B
WUXI APPTEC CO., LTD.	-43.53%	16.17B
NEUROCRINE BIOSCIENCES, INC.	+2.03%	13.17B
SAREPTA THERAPEUTICS, INC.	+25.98%	11.11B

Bio Therapeutic Drugs